创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

冀倩倩, 朱士茂, 吴彦萍, 吴樱丹, 陈楚如, 李云富, 郭采平. 重组人长效凝血因子Ⅶ药物研发进展[J]. 药学进展, 2019, 43(3): 226-230.
引用本文: 冀倩倩, 朱士茂, 吴彦萍, 吴樱丹, 陈楚如, 李云富, 郭采平. 重组人长效凝血因子Ⅶ药物研发进展[J]. 药学进展, 2019, 43(3): 226-230.
JI Qianqian, ZHU Shimao, WU Yanping, WU Yingdan, CHEN Churu, LI Yunfu, GUO Caiping. Research Progress in R&D of Recombinant Human Long-acting Coagulation Factor VⅡ[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 226-230.
Citation: JI Qianqian, ZHU Shimao, WU Yanping, WU Yingdan, CHEN Churu, LI Yunfu, GUO Caiping. Research Progress in R&D of Recombinant Human Long-acting Coagulation Factor VⅡ[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 226-230.

重组人长效凝血因子Ⅶ药物研发进展

Research Progress in R&D of Recombinant Human Long-acting Coagulation Factor VⅡ

  • 摘要: 凝血因子Ⅶ(FVⅡ)是一种广泛应用于治疗和预防伴发抑制物的血友病患者出血并发症的旁路制剂。诺和诺德的重组活性FVⅡ(rFVⅡa)至今仍是全球唯一的商业化rFVⅡa产品。因rFVⅡa半衰期短、需多次注射,限制了其在血友病预防和治疗中的应用。总结了国内外近年来正在开发的长效rFVⅡa药物及其研究进展,包括在聚乙二醇修饰、序列突变和融合蛋白等技术下研制的长效rFVⅡa产品,详细介绍了各自的长效机制和药物研发进展,旨在为长效rFVⅡa药物的研发提供参考。

     

    Abstract: Coagulation factor VⅡ (FVⅡ) is a bypassing agent widely used in the treatment of bleeding in hemophilia patients with inhibitors. Novo Nordisk's NovoSeven is still the only commercially available recombinant activated FVⅡ (rFVⅡa) product in the world. However, its halflife is short and multiple injections are needed, which limits its application in the prevention and treatment of hemophilia. In this review, the longacting rFVⅡa products that are urgently under development were summarized, including those developed through PEG modification, sequence mutation and fusion protein technology. Their respective mechanisms and development progress were described, so as to provide reference for the development of long-acting rFVⅡa protein.

     

/

返回文章
返回